莱沃多巴治疗:整个帕金森病进展过程中的影响和机制
Peter Riederer1,2, Sabrina Strobel3, Toshiharu Nagatsu4
1Clinic and Policlinic for Psychiatry, Psychosomatics and Psychotherapy, University Hospital Wuerzburg, University of Wuerzburg, Würzburg, Germany.
Journal of neural transmission (Vienna, Austria : 1996)
|April 11, 2025
概括
对于帕金森病 (PD) 的利沃多巴治疗在晚期由于多巴胺 (DA) 损失而面临挑战,导致运动波动,如功能障碍和OFF阶段. 战略重点是持续的药物输送和辅助药物,以管理这些晚期PD症状.
科学领域:
- 神经科学是一个神经科学.
- 药理学 药理学是指药理学的学科.
- 神经学 神经学
背景情况:
- 50多年来,利沃多巴一直是帕金森病 (PD) 的基石疗法,旨在补充多巴胺 (DA) 水平.
- 晚期PD的特点是渐进的多巴胺基神经元退化,导致内源性DA减少和DA功能受损.
- 这种退化损害了大脑的自然DA缓冲能力,使得利沃多巴治疗不那么稳定.
研究的目的:
- 审查在晚期帕金森病中使用乐伏多巴治疗时遇到的挑战的科学基础.
- 探索运动波动背后的机制,包括晚期PD的Levodopa诱导的动力障碍 (LID) 和OFF阶段.
- 讨论目前的管理策略,以优化勒沃多巴治疗在晚期PD.
主要方法:
- 关于在帕金森病中使用莱沃多巴治疗的科学文献的综述.
- 分析影响DA平衡的PD条状体中神经生物学变化的分析.
- 检查神经可塑性和非多巴胺基变性在治疗反应中的作用.
主要成果:
- 在晚期PD中,对利沃多巴的依赖性增加导致明显的条纹性DA波动.
- 这些波动是由于失去了DA缓冲能力和改变了非多巴胺基神经元的DA释放而产生的.
- 运动并发症 (LID和OFF阶段) 由这些DA水平变化引起.
结论:
- 管理晚期PD需要解决levodopa治疗的挑战,包括运动波动.
- 诸如连续输送利沃多巴和辅助药物 (例如MAO-B抑制剂,阿曼塔丁) 等策略可以缓解症状.
- 了解高级PD的复杂神经生物学对于完善治疗方法至关重要.
相关概念视频
01:24Parkinson's Disease: Treatment
158
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
158
01:15Parkinson's Disease: Overview
334
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
334
01:29Drugs Affecting Neurotransmitter Synthesis
1.2K
Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase,...
1.2K
01:28Drugs Affecting GI Tract Motility: Dopamine Receptor Antagonists
204
Prokinetic agents are specialized medications that stimulate gastrointestinal (GI) motility, promoting food movement through the GI tract. Dopamine, an inhibitory neurotransmitter, plays a significant role in this process, reducing GI motility and indirectly controlling the speed of digestion. Dopamine receptor antagonists, such as metoclopramide and domperidone, offer a unique advantage as prokinetic agents. By blocking the dopamine receptors, these drugs increase GI motility, improving food...
204
01:22Alzheimer's Disease: Treatment
132
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
132
01:37Neural Regulation
39.0K
Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
39.0K